Combined expression of HLA-DR antigen and proliferating cell nuclear antigen correlate with colorectal cancer prognosis.
HLA-DR antigen expression and the proliferating cell nuclear antigen labeling index (PCNA-LI) were examined immmunohistochemically in 59 surgically resected advanced colorectal cancers to clarify the clinicopathologic significance of the HLA-DR antigen. HLA-DR antigen expression was detected in 33 (56%) of the 59 lesions, which showed less frequent liver metastasis than lesions without HLA-DR antigen expression (40 vs. 68%; p < 0.05). Five-year survival rates of patients with and without HLA-DR antigen expression were 50 and 19%, respectively. Lesions combining HLA-DR antigen expression and a relatively low PCNA-LI had the best prognosis. These results indicate that HLA-DR antigen expression, particularly combined with a low PCNA-LI, is an important outcome predictor in colorectal cancer.
Kunihiro
M
M
First Department of Internal Medicine, Hiroshima University School of Medicine, Japan.
Tanaka
S
S
Haruma
K
K
Yoshihara
M
M
Sumii
K
K
Kajiyama
G
G
Shimamoto
F
F
D000368:Aged; D000911:Antibodies, Monoclonal; D015179:Colorectal Neoplasms / Q000276:immunology* / Q000473:pathology; D005260:Female; D005786:Gene Expression Regulation; D015972:Gene Expression Regulation, Neoplastic; D006684:HLA-DR Antigens / Q000096:biosynthesis*; D006801:Humans; D007150:Immunohistochemistry; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000096:biosynthesis*; D016019:Survival Analysis
D000911:Antibodies, Monoclonal; D006684:HLA-DR Antigens; D018809:Proliferating Cell Nuclear Antigen